MENU

en menu

Articles

  • KSBNS 2024

Article Tools

View Full Text Abstract
Article as PDF Print this Article
Pubmed PMC
PubReader Export to Citation
Email Alerts Open Access

Share this article on :

Stats or Metrics

Related articles in EN

Article

Original Article

Exp Neurobiol 2017; 26(1): 33-41

Published online February 28, 2017

https://doi.org/10.5607/en.2017.26.1.33

© The Korean Society for Brain and Neural Sciences

M2 Phenotype Microglia-derived Cytokine Stimulates Proliferation and Neuronal Differentiation of Endogenous Stem Cells in Ischemic Brain

Ja Yong Choi1,2†, Jong Youl Kim1†, Jae Young Kim1†, Joohyun Park1,2, Won Taek Lee1 and Jong Eun Lee1,2*

1Department of Anatomy, Yonsei University College of Medicine, 2BK21 Plus Project for Medical Sciences and Brain Research Institute, Yonsei University College of Medicine, Seoul 03722, Korea

Correspondence to: *To whom correspondence should be addressed.
TEL: 82-2-2228-1646, FAX: 82-2-365-0700
e-mail: jelee@yuhs.ac
†These authors contributed equally to this work.

Received: January 13, 2017; Revised: January 20, 2017; Accepted: January 23, 2017

Abstract

Microglia play a key role in the immune response and inflammatory reaction that occurs in response to ischemic stroke. Activated microglia promote neuronal damage or protection in injured brain tissue. Extracellular signals polarize the microglia towards the M1/M2 phenotype. The M1/M2 phenotype microglia released pro- and anti-inflammatory cytokines which induce the activation of neural stem/progenitor cells (NSPCs). In this study, we investigated how the cytokines released by microglia affect the activation of NSPCs. First, we treated BV2 cells with a lipopolysaccharide (LPS; 20 ng/ml) for M1 phenotype microglia and interleukin-4 (IL-4; 20 ng/ml) for M2 phenotype microglia in BV2 cells. Mice were subjected to transient middle cerebral artery occlusion (tMCAO) for 1 h. In ex vivo, brain sections containing the subventricular zone (SVZ) were cultured in conditioned media of M1 and M2 phenotype-conditioned media for 3 d. We measured the expression of cytokines in the conditioned media by RT-PCR and ELISA. The M2 phenotype microglia-conditioned media led to the proliferation and neural differentiation of NSPCs in the ipsilateral SVZ after ischemic stroke. The RT-PCR and ELISA results showed that the expression of TGF-α mRNA was significantly higher in the M2 phenotype microglia-conditioned media. These data support that M2 phenotype microglia-derived TGF-α is one of the key factors to enhance proliferation and neural differntiation of NSPCs after ischemic stroke.

Keywords: Ischemic stroke, TGF-α, microglia, neural stem/progenitor cells, proliferation, neuronal differentiation

INTRODUCTION

Stroke is the dangerous disease accounting for the leading cause of death or disorder worldwide. While stroke has a high mortality rate and causes serious suffer after recovery, there is no complete therapy. In ischemic stroke, inflammatory cells such as macrophage and monocyte move into the lesion area [1,2]. Furthermore, microglia can quickly undergo morphologic transformation from a resting condition to an activating condition, where they become virtually indistinguishable from circulating macrophages [3,4]. Activated microglia have been shown to release a variety of cytokines contributing to cell damage or cell repair leading to exacerbated brain injury [5]. In ischemic stroke, resting microglia can be polarized to the M1 phenotype, or alternatively to prophagocytic M2 phenotype through different signals [6,7,8]. The M1 phenotype promotes the transcriptional activation of nuclear factor-kB (NF-kB) and generates high levels of pro-inflammatory cytokines and oxidative metabolites [9]. In contrast, the M2 phenotype is triggered by anti-inflammatory cytokines [10,11], which are thought to inhibit inflammation and enhance tissue repair and wound healing [12].

In ischemic stroke, the progenitor cells in SVZ become into a new neural cell that could be one of the therapies to neurogenesis [13]. Following focal ischemia, enhanced neurogenesis including an increased proliferation of neural progenitors in the ipsilateral SVZ, migration of neuroblasts from the SVZ to the injured striatum, and functional differentiation and integration of newly generated cells in the damaged brain has been observed in many studies [14]. Activated microglia accumulate in postnatal SVZ and induce neurogenesis and oligodendrogenesis via released cytokines [15]. We and others have investigated how microglia affect the activation of progenitor cells in the SVZ after ischemic stroke. This is still unclear and controversial.

Therefore, the objective of this study is to explore further the effect of microglia-derived cytokine on the process of proliferation, neurogenesis and neural differentiation of NSPCs in SVZ after ischemic stroke.

MATERIALS AND METHODS

BV2 cell culture

Murine BV2 cell line, which was originally immortalized after infection with a v-raf/v-myc recombinant retrovirus [16], and maintained at 37℃ at 5% CO2 at Roswell Park Memorial Institute (RPMI)-1640 (Thermo Scientific) with 10% fetal bovine serum (FBS; Thermo Scientific) and 1% penicillin/streptomycin (Thermo Scientific). To polarize the M1 phenotype activated by LPS or M2 phenotype activated by IL-4, BV2 cells were treated with LPS (20 ng/ml, Sigma-Aldrich) and IL-4(20 ng/ml, cell signaling), respectively. Cultured media containing the BV2 cells were transferred to serum-free RPMI-1640 media after 24 h stimulation and cultured further for 48 h. The serum-free RPMI-1640 conditioned media was collected with a 0.22 µm filter and stored at -70℃ until use [13]. To determine the role of TGF-α in M2 conditioned media, TGF-α antibody (0.2 ng/ml) was added to the M2 conditioned media for TGF-α neutralization. The control media used serum-free RPMI-1640 media.

Experimental animals

Adult male ICR mice (8 weeks old, Coatech) were used in this study and kept under a 12 h light/dark cycle with freely accessible food and water. All animal experiments were approved by the Committee for the Care and Use of Laboratory Animals at Yonsei University Health System (2011-0212) and performed in accordance with the National Institute of Health guidelines for the Care and Use of Laboratory Animals.

Transient middle cerebral artery occlusion

Three days prior to tMCAO, all experimental animals were labeled with 5-bromo-2′-deoxyuridine (BrdU; 50 mg/kg, daily intraperitoneal (IP) injection, Sigma-Aldrich). Before the surgery, animals were anesthetized with Zoletil50® (30 mg/kg) and Rompun (10 mg/kg). Body temperature was maintained 37.5℃ with a heating pad. Ischemic stroke was induced using an intraluminal stature as described earlier [17]. In brief, an uncoated 15 mm segment of 6-0 nylon mono filament suture with the tip rounded by a flame was inserted into the internal carotid artery via common carotid artery until the suture occluded the middle cerebral artery. After 60 min occlusion, the suture was removed and surgical incisions were closed. Animals were kept on the heating pad before awakening. Food and water were freely accessible in their cages.

Immunocytochemistry

The characteristics of the BV2 cells after LPS or IL-4 induced stimulation were confirmed by immunocytochemistry. Samples were fixed with 4% paraformaldehyde, permeabilized with PBS in 0.025% Triton X-100 and blocked with goat serum at room temperature (RT). Primary antibodies as anti-rabbit CD68 (1:200, Santa Cruz) and anti-goat CD206 (1:200, Santa Cruz) were incubated for 3 h at RT. Samples were washed with PBS. The samples were incubated with Alexa-488 donkey anti-rabbit and Alexa-594 donkey anti-goat (1:200, Santa Cruz) for 1 h at RT. The samples were washed with PBS and counterstained with 1 µg/ml 4′,6-diamidino-2-phenylindole (DAPI; 1:500, Invitrogen) for 1 min at RT.

Organotypic cultures of nervous tissue

Organotypic culture was prepared according to a previously decribed method [18]. After 6 h reperfusion, Mice were decapitated atfer 6 h reperfusion. The extracted brain samples were embedded in 5% low melting agarose gel and hardened at RT. The embedded brains were serially cut in the coronal plane into 200 µm thick sectins using a vibratome. The sectioned brains were transiently stored in artificial cerebrospinal fluid (ACSF; 119 mM NaCl, 26.2 mM NaHCO3, 2.5 mM KCl, 1 mM NaH2PO4, 1.3 mM MgCl2, 10 mM glucose, and 2.5 mM CaCl2). ACSF was sterilized with a 0.22 µm filter apparatus and oxygenated with 95% O2 and 5% CO2 for 10~15 min before use. The sliced brains with SVZ region were placed on a cell culture insert with 0.4 µm pore size (FALCON) in 6-well plates. The cell culture inserts were filled with 2 ml conditioned media (M0, M1, and M2 phenotypes). The sliced brain samples were incubated in 5% CO2 incubator at 37℃ for 72 h.

Immunohistochemistry

All samples were fixed with 4% paraformaldehyde for 1 h and then washed with PBS with 1% Tween-20. For BrdU staining, the sliced brains were rinsed in PBS, denatured in 4 N HCl at RT for 30 min, and neutralized in 0.1 M boric acid for 10 min. Samples were rinsed and blocked with PBS include 10% FBS and 1% Tween 20. Primary antibodies of anti-rabbit Ki67 (1:500, Abcam), anti-mouse BrdU (1:200, Thermo Scientific), anti-rabbit DCX (1:200, Abcam), anti-rabbit NeuN (1:200, Abcam), and anti-rabbit Olig2 (1:200, Abcam) were added to the samples and incubated for 48 h at 4℃. Samples were washed with PBS with 1% Tween 2, followed by incubation with Alexa-594 donkey anti-rabbit and Alexa-488 donkey anti-mouse (1:200, Santa Cruz) at RT for 1 h. Samples were washed with PBS and stained with 1 µg/ml 4′,6-diamidino-2-phenylindole (DAPI; 1:500, Invitrogen) for 3 min at RT. The stained brain samples were captured using LSM 700 confocal microscope (Carl Zeiss).

Reverse transcription polymerase chain reaction

Total RNA was extracted from BV2 cells by TRIzol (Invitrogen) following the instructions protocol and the mRNA was quantified by spectrophotometric analysis. Total RNA (2 µg) from each sample was transcribed into cDNA and synthesized PCR amplicon using SuperScript III One-Step RT-PCR System with platinum® Taq DNA Polymerase (Invitrogen) according to the manufacturer's instructions; The following primers were used: TGF-α primer pairs forward: TACCGCTGGGTATCCTGTTA and reverse: TTCTCATGTCTGCAGACGAG, IL-10 primer pairs forward: CCAAGCCTTATCGGAAATGA and reverse: TTTTCACAGGGGAGAATCG and GAPDH primer pairs forward: TGGCACAGTCAAGGCTGAGA and reverse: CTTCTGAGTGGCAGTGATGG. The thermal cycling conditions were set to 95℃ for 10 min, followed by 95℃ for 15 sec, 60℃ for 30 sec, and 68℃ for 1 min, repeated 40 times. The mRNA expression was normalized to the levels of GAPDH.

ELISA assay

To determine the soluble TGF-α concentration in the different phenotypes of supernatant in BV2 cells, the conditioned media were measured by the mouse TGF-α ELISA Kit (E-EL-M1190, Elabscience) according to the manufacturer's instructions. All steps were performed at 37℃. In a 96-well plate which is coated with the capture antibody, 100 ul of the standard solution, blank and samples were loaded for 90 min incubation. Absorbance was read at 450 nm using a microplate reader.

Statistical analysis

Statistical comparisons were made between multiple groups using analysis of variance (ANOVA) followed by Tukey's Honestly significant difference (HSD) test. The level of significance was set at p≤0.05. Data were expressed as the mean±standard deviation (SD).

RESULTS

LPS or IL-4 induce M1/M2 type polarization of BV2 microglia cell

To confirm the polarization of microglia, BV2 microglia were treated with the LPS (M1 phenotype) or IL-4 (M2 phenotype) (Fig. 1A). After 72 h incubation, these supernatants were harvested in the M1 conditioned media and M2 conditioned media, respectively, from the BV2 cell culture. Serum free RPMI 1640 media were labeled as M0 conditioned media (M0 CM). We performed immunocytochemistry against CD 68 (M1 phenotype) and CD 206 (M2 phenotype) [19] in BV2 microglia cells polarized by LPS or IL-4 for 72 h (Fig. 1B). Overexpression of CD68 was observed in BV2 cells induced by M1 conditioned media, however, CD68 expression decreased in M2 conditioned media. CD206 expression was observed only in BV2 microglia cells induced by M2 conditioned media.

M2 conditioned media stimulates the cellular proliferation in SVZ of the organotypic brain after ischemic stroke

To investigate whether M0, M1, and M2 conditioned media affect cellular proliferation in SVZ of the organotypic brain after ischemic stroke, ex vivo organotypic culture was performed in 3 different conditioned media for 3 d (Fig. 2A). Ki67 expression increased significantly during the G1-, S-, M- and G2-phase of the cell cycle. BrdU incorporate into the newly synthesized DNA strands of S-phase cells and is useful for estimating the fraction of cells in S-phase. We counted the number of Ki67+ and BrdU+-double labeled cells to confirm the cellular proliferation in SVZ for 7 d after ischemic stroke. Immunohistochemistry showed that Ki67+ and BrdU+-double labeled cells were significantly increased in M2 conditioned media compared with M0 and M1 conditioned media (Fig. 2B and 2C). These results suggest that M2 conditioned media strongly promoted the cellular proliferation in SVZ after ischemic stroke.

M2 conditioned media stimulates the neurogenesis, oligodendrogenesis and neural differentiation of SVZ-NSPCs in the organotypic brain after ischemic stroke

To determine the characteristics of proliferating in SVZ of the organotypic brain after ischemic stroke, immunohistochemistry was performed using doublecortin (DCX), NeuN, Olig2, and BrdU. DCX, which is a microtubule-associated protein essential for the migration of neurons in the human brain, is highly expressed in neuronal progenitor cells or migrating neuroblasts. The results showed that M2 conditioned media significantly increased DCX+ and BrdU+ cells in SVZ compared with M0 and M1 conditioned media after ischemic stroke. The quantification graph shows significantly increased cell number in M2 conditioned media (Fig. 3A and 3B). Next, to determine the neural differentiation of SVZ-NSPCs after ischemic stroke, immunohistochemistry was performed using NeuN, Olig2, and BrdU were performed. NeuN reacts with most neuronal cells in the nervous system. The results showed that M2 conditioned media significantly increased NeuN+ and BrdU+ cells in SVZ compared with M1 conditioned media after ischemic stroke. The quantification graph shows significantly increased cell number in the M2 conditioned media (Fig. 3C and 3D). Olig2 is specifically expressed in nervous tissue as a gene regulator of oligodendrogenesis. The result showed that M2 conditioned media was significantly increased Olig2+ and BrdU+ cells in SVZ compared with M0 and M1 conditioned media after ischemic stroke. The quantification graph shows significantly increased cell number in M2 conditioned media (Fig. 3E and 3F). Together, these results ascertain that M2 conditioned media promotes the neurogenesis, oligodendrocyte and neural differentiation of SVZ-NSPCs after ischemic stroke.

TGF-α is one of the major cytokines in M2 conditioned media

Using RT-PCR and ELISA, we subsequently identified a key cytokine in M2 conditioned media, which promoted the proliferation, neurogenesis and neural differentiation of SVZ-NSPCs after ischemic stroke. The expression of IL-10 and TGF-α mRNA was significantly increased in M2 conditioned media compared with M0 and M1 conditioned media (Fig. 4A and 4B). ELISA assay was performed to quantitate TGF-α in the M2 conditioned media. The data showed that the level of TGF-α was significantly increased in M2 conditioned media compared with M0 and M1 conditioned media (Fig. 4C). The results indicate that TGF-α is one of the major cytokines in M2 conditioned media and may be affected in the proliferation, neurogenesis, and neural differentiation of SVZ-NSPCs after ischemic stroke.

TGF-α plays key role in the proliferation and neurogensis of SVZ-NSPCs after ischemic stroke

To investigate the role of TGF-α in the proliferation, neurogenesis, and neural differentiation of SVZ-NSPCs, we treated the SVZ-NSPCs with or without neutralizing antibody against TGF-α in M2 conditioned media. Immunohistochemistry analyses revealed that Ki67+ and BrdU+ of SVZ-NSPCs was significantly increased (1.6 fold) in no neutralized TGF-α in M2 conditioned media (Fig. 5A and 5B). Next, we assessed the neural progenitor cells or migrating neuroblasts of SVZ-NSPCs after ischemic stroke using immunohistochemistry of DCX and BrdU. This data showed that DCX+ and BrdU+ of SVZ-NSPCs was significantly increased (1.8 fold) in non-neutralizing TGF-α in M2 conditioned media (Fig. 5C and 5D). To determine the neuronal differentiation of SVZ-NSPCs after ischemic stroke, immunohistochemistry was performed using NeuN and BrdU. This data showed that the number of NeuN+ and BrdU+ of SVZ-NSPCs did not significantly change, but not change with or without neutralizing TGF-α in M2 conditioned media (Fig. 5E and 5F). To determine the oligodendrogenesis of SVZ-NSPCs after ischemic stroke, immunohistochemistry was conducted using Olig2 and BrdU. This data showed that the number of Olig2+ and BrdU+ cells of SVZ-NSPCs also slightly increased, but not changed with or without neutralizing TGF-α in M2 conditioned media (Fig. 5G and 5H). Therefore, these results suggest that TGF-α might play a key role in the proliferation and neurogenesis of SVZ-NSPCs after ischemic stroke, but not in neural differentiation.

DISCUSSION

Neural stem cells (NSCs) are mainly located on the subgranular zone of the dentate gyrus of the hippocampus and the forebrain SVZ in the postnatal mammalian brain [20,21]. Numerous studies demonstrated that activated microglia are important in neurogenesis in the adult SVZ; however, microglial contribution to neurogenesis is complex [22,23]. Recently, the role of microglia in neurogenesis has been examined mainly in pathological conditions [24,25]. Microglia, which is a kind of immune cell, perform main function of immune response in the brain [26,27,28]. Microglia have two efficiencies which are totally different effects. Once activated by extracellular signals, activated microglia have predominantly harmful effects in the acute stages of ischemic stroke, and that most beneficial effects appear in delayed stages [29,30]. Microglia also play diverse roles in neurogenesis in both the embryonic and postnatal adult stages [31]. Recently, a study demonstrated that microglia related to neurogenesis of embryonic SVZ. During the late stages of cortical neurogenesis, microglia regulated the size of the neuronal precursor pool through the phagocytosis of Tbr21 and Pax61 cells [32]. Remarkably, most precursor cells, which were targeted by microglia, did not undergo cell death. Activated microglia accumulate in the SVZ during the early postnatal period and then disperse to white matter where they became more ramified. In in vivo and in vitro studies, activated microglia in the early postnatal SVZ also enhanced neurogenesis and oligodendrogenesis via the released cytokine [15]. The enhancement of neurogenesis was suppressed by a combination of function-blocking antibodies to cytokines, but not by any single antibody in the in vitro co-culture system of NSPCs and microglia [15]. This variability in the effects of microglia on neurogenesis displayed the different polarizations of microglia and/or the precise status of NSCs/neuronal progenitor cells (NPCs) [33,34,35] and crosstalk between them [36]. Another study showed that microglia-conditioned media rescue the in vitro formation of neuroblasts from NSPCs in SVZ [37]. To determine the role of activated microglia in functional neurogenesis, we collected M1 and M2 phenotype microglia-conditioned media and found that M2 phenotype microglia released TGF-α.

TGF-α is a member of the epidermal growth factor (EGF) family that actives the EGF-receptor (EGF-R) trans-membrane tyrosine kinase [38,39]. This mechanism shows that the increase in intracellular calcium levels, glycolysis and expression of certain genes, such as EGF-R gene, ultimately lead to DNA synthesis and cell proliferation [40]. Both TGF-α and EGF-R are located in the SVZ where they regulate the activity of neural progenitor cells [41]. Previous reports have suggested that TGF-α also significantly amplify the proliferative responses of neural stem cells in the SVZ [42], but causes minimal migration in response [43]. In the ischemic stroke model, intraventricular TGF-α also reduced the infarct volumes. These neuroprotective effects are driven by anti-apoptotic and anti-inflammatory mechanisms [44]. Recently, study also showed that macrophage secrete TGF-α and even when the tissue was culutred in media including TGF-α from surrounding infarct lesion, this protective effect was maintained [42].

In the current study, we found that M2 phenotype microglia release TGF-α, whic it may be affect the neurogenesis of NSPCs in SVZ. This event was associated with the effect of TGF-α on the proliferation and migration of NSPCs. However, in the current study, we failed to see any changes of neuron and oligodendrocyte of SVZ-NSPCs with or without TGF-α in M2 conditioned media. We report for the first time that microglia-derived TGF-α plays a role in the proliferation and neurogenesis of NSPCs in the SVZ after ischemic stroke and is involved in neurological recovery. We also suggest that microglia-derived cytokines should be studied further in neurogenesis related brain injury.

Figures

Fig. 1. Polarization of BV2 microglial cells using conditioned media. (A) Schematic time course of the in vitro experiments. (B) Immunohistochemistry of CD68 (M1 phenotype microglia; green) and CD206 (M2 phenotype microglia; red). In BV2 microglial cell, the expression of CD68 significantly increased in M1 conditioned media compared with M2 conditioned media. CD206 is expressed only in M2 conditioned media (Scale bar=20 um, n=5/group).
Fig. 2. Proliferation SVZ-NSPCs in M2 conditioned media. (A) Schematic time course of the in vivo and ex vivo experiments. (B) Immunohistochemistry of Ki67 and BrdU in M0, M1, and M2 conditioned media shows the proliferation of SVZ-NSPCs in THE organotypic brain. (C) Quantification graph of the ratio of Ki67+ and BrdU+ cells of SVZ-NSPCs in organotypic brain (Scale bar=20 um, **p<0.05 vs. M0 conditioned media, n=5/group).
Fig. 3. Differentiation of SVZ-NSPCs in M2 conditioned media. M0, M1, or M2 conditioned media induced the differentiation of SVZ-NSPCs in the organotypic brain. (A and B) Immunohistochemistry and quantification graph of the ratio of DCX+ and BrdU+ cells of SVZ-NSPCs in the organotypic brain. (C and D) Immunohistochemistry and quantification graph of the ratio of NeuN+ and BrdU+ cells of SVZ-NSPCs in the organotypic brain. (E and F) Immunohistochemistry and quantification graph of the ratio of Olig2+ and BrdU+ cells of SVZ-NSPCs in the organotypic brain (Scale bar=20 um; **p<0.05, ***p<0.01 vs. M0 conditioned media; n=5/group).
Fig. 4. TGF-α is one of the major cytokines in M2 conditioned media. (A) RT-PCR of IL-10 and TGF-α in M0, M1, or M2 conditioned media. IL-10 and TGF-α expression is significantly increased at the mRNA level in M2 conditioned media. (B) The graph depicts the relative mRNA expression of IL-10 and TGF-α in M0, M1, and M2 conditioned media. The expression of these genes is significantly increased in M2 conditioned media. (C) The expression level of TGF-α in M0, M1, and M2 conditioned media using ELISA assay. The quantity of TGF-α is significantly increased in M2 conditioned media compared with M1 (***p<0.01 vs. M0 conditioned media, n=5/group).
Fig. 5. Effect of TGF-α on the proliferation and neurogenesis of SVZ-NSPCs after cerebral ischemia. (A and B) Immunohistochemistry and quantification graph of the ratio of Ki67+ and BrdU+ cells of SVZ-NSPCs in the organotypic brain. (C and D) Immunohistochemistry and quantification graph of the ratio of DCX+ and BrdU+ cells of SVZ-NSPCs in organotypic brain. (E and F) Immunohistochemistry and quantification graph of the ratio of NeuN+ and BrdU+ cells of SVZ-NSPCs in the organotypic brain. (G and H) Immunohistochemistry and quantification graph of the ratio of Olig2+ and BrdU+ cells of SVZ-NSPCs in the organotypic brain (Scale bar=20 um, **p<0.05 vs M0 conditioned media, n=5/group).

References

  1. Yilmaz G, Granger DN. Cell adhesion molecules and ischemic stroke. Neurol Res 2008;30:783-793.
    Pubmed
  2. Härtl R, Schürer L, Schmid-Schönbein GW, del Zoppo GJ. Experimental antileukocyte interventions in cerebral ischemia. J Cereb Blood Flow Metab 1996;16:1108-1119.
    Pubmed
  3. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 2011;11:775-787.
    Pubmed
  4. Appel SH, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in ALS. Acta Myol 2011;30:4-8.
    Pubmed
  5. Lai AY, Todd KG. Microglia in cerebral ischemia: molecular actions and interactions. Can J Physiol Pharmacol 2006;84:49-59.
    Pubmed
  6. Chawla A. Control of macrophage activation and function by PPARs. Circ Res 2010;106:1559-1569.
    Pubmed
  7. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 2010;10:453-460.
    Pubmed
  8. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964.
    Pubmed
  9. Kawabori M, Yenari MA. The role of the microglia in acute CNS injury. Metab Brain Dis 2015;30:381-392.
    Pubmed
  10. Nguyen KD, Qiu Y, Cui X, Goh YP, Mwangi J, David T, Mukundan L, Brombacher F, Locksley RM, Chawla A. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 2011;480:104-108.
    Pubmed
  11. Nair MG, Guild KJ, Artis D. Novel effector molecules in type 2 inflammation: lessons drawn from helminth infection and allergy. J Immunol 2006;177:1393-1399.
    Pubmed
  12. Colton CA. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 2009;4:399-418.
    Pubmed
  13. Ajmone-Cat MA, Mancini M, De Simone R, Cilli P, Minghetti L. Microglial polarization and plasticity: evidence from organotypic hippocampal slice cultures. Glia 2013;61:1698-1711.
    Pubmed
  14. Lichtenwalner RJ, Parent JM. Adult neurogenesis and the ischemic forebrain. J Cereb Blood Flow Metab 2006;26:1-20.
    Pubmed
  15. Shigemoto-Mogami Y, Hoshikawa K, Goldman JE, Sekino Y, Sato K. Microglia enhance neurogenesis and oligodendrogenesis in the early postnatal subventricular zone. J Neurosci 2014;34:2231-2243.
    Pubmed
  16. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol 1990;27:229-237.
    Pubmed
  17. Kim JH, Lee YW, Park KA, Lee WT, Lee JE. Agmatine attenuates brain edema through reducing the expression of aquaporin-1 after cerebral ischemia. J Cereb Blood Flow Metab 2010;30:943-949.
    Pubmed
  18. Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 1991;37:173-182.
    Pubmed
  19. Perego C, Fumagalli S, De Simoni MG. Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J Neuroinflammation 2011;8:174.
    Pubmed
  20. Zerlin M, Milosevic A, Goldman JE. Glial progenitors of the neonatal subventricular zone differentiate asynchronously, leading to spatial dispersion of glial clones and to the persistence of immature glia in the adult mammalian CNS. Dev Biol 2004;270:200-213.
    Pubmed
  21. Doetsch F, Scharff C. Challenges for brain repair: insights from adult neurogenesis in birds and mammals. Brain Behav Evol 2001;58:306-322.
    Pubmed
  22. Goings GE, Kozlowski DA, Szele FG. Differential activation of microglia in neurogenic versus non-neurogenic regions of the forebrain. Glia 2006;54:329-342.
    Pubmed
  23. Temple S. The development of neural stem cells. Nature 2001;414:112-117.
    Pubmed
  24. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A 2003;100:13632-13637.
    Pubmed
  25. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003;302:1760-1765.
    Pubmed
  26. Nikolakopoulou AM, Dutta R, Chen Z, Miller RH, Trapp BD. Activated microglia enhance neurogenesis via trypsinogen secretion. Proc Natl Acad Sci U S A 2013;110:8714-8719.
    Pubmed
  27. Kokaia Z, Martino G, Schwartz M, Lindvall O. Crosstalk between neural stem cells and immune cells: the key to better brain repair?. Nat Neurosci 2012;15:1078-1087.
    Pubmed
  28. Krathwohl MD, Kaiser JL. Chemokines promote quiescence and survival of human neural progenitor cells. Stem Cells 2004;22:109-118.
    Pubmed
  29. Mittelbronn M, Dietz K, Schluesener HJ, Meyermann R. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol 2001;101:249-255.
    Pubmed
  30. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007;10:1387-1394.
    Pubmed
  31. Sato K. Effects of microglia on neurogenesis. Glia 2015;63:1394-1405.
    Pubmed
  32. Cunningham C. Microglia and neurodegeneration: the role of systemic inflammation. Glia 2013;61:71-90.
    Pubmed
  33. Cacci E, Ajmone-Cat MA, Anelli T, Biagioni S, Minghetti L. In vitro neuronal and glial differentiation from embryonic or adult neural precursor cells are differently affected by chronic or acute activation of microglia. Glia 2008;56:412-425.
    Pubmed
  34. Ekdahl CT. Microglial activation - tuning and pruning adult neurogenesis. Front Pharmacol 2012;3:41.
    Pubmed
  35. Ortega F, Gascón S, Masserdotti G, Deshpande A, Simon C, Fischer J, Dimou L, Chichung Lie D, Schroeder T, Berninger B. Oligodendrogliogenic and neurogenic adult subependymal zone neural stem cells constitute distinct lineages and exhibit differential responsiveness to Wnt signalling. Nat Cell Biol 2013;15:602-613.
    Pubmed
  36. Mosher KI, Andres RH, Fukuhara T, Bieri G, Hasegawa-Moriyama M, He Y, Guzman R, Wyss-Coray T. Neural progenitor cells regulate microglia functions and activity. Nat Neurosci 2012;15:1485-1487.
    Pubmed
  37. Walton NM, Sutter BM, Laywell ED, Levkoff LH, Kearns SM, Marshall GP, Scheffler B, Steindler DA. Microglia instruct subventricular zone neurogenesis. Glia 2006;54:815-825.
    Pubmed
  38. Irvin DK, Dhaka A, Hicks C, Weinmaster G, Kornblum HI. Extrinsic and intrinsic factors governing cell fate in cortical progenitor cultures. Dev Neurosci 2003;25:162-172.
    Pubmed
  39. Cameron HA, Hazel TG, McKay RD. Regulation of neurogenesis by growth factors and neurotransmitters. J Neurobiol 1998;36:287-306.
    Pubmed
  40. Xian CJ, Zhou XF. Roles of transforming growth factor-alpha and related molecules in the nervous system. Mol Neurobiol 1999;20:157-183.
    Pubmed
  41. Kornblum HI, Hussain RJ, Bronstein JM, Gall CM, Lee DC, Seroogy KB. Prenatal ontogeny of the epidermal growth factor receptor and its ligand, transforming growth factor alpha, in the rat brain. J Comp Neurol 1997;380:243-261.
    Pubmed
  42. Leker RR, Toth ZE, Shahar T, Cassiani-Ingoni R, Szalayova I, Key S, Bratincsák A, Mezey E. Transforming growth factor alpha induces angiogenesis and neurogenesis following stroke. Neuroscience 2009;163:233-243.
    Pubmed
  43. Cooper O, Isacson O. Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons. J Neurosci 2004;24:8924-8931.
    Pubmed
  44. Justicia C, Pérez-Asensio FJ, Burguete MC, Salom JB, Planas AM. Administration of transforming growth factor-alpha reduces infarct volume after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 2001;21:1097-1104.
    Pubmed

Print ISSN : 1226-2560

Online ISSN : 2093-8144

© 2019. Experimental Neurobiology: the official journal of the Korean Society for Brain and Neural Sciences & the Korean Society for Neurodegenerative Disease.